NovaBay Pharmaceuticals Expands Avenova® Consumer Marketing through Affiliate Programs and Enhanced Lifestyle Public Relations
September 24 2020 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
expanded Avenova® consumer marketing programs designed to generate
greater awareness of its antimicrobial lid and lash spray and
promote online sales. NovaBay has engaged PartnerCentric, Inc. for
affiliate marketing programs and HVM Communications for enhanced
public relations featuring consumer-oriented, lifestyle
messaging.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200924005274/en/
“Since engaging PartnerCentric only days ago we are already
having success in gaining awareness of Avenova through websites
featuring banner advertising and postings, with an impressive
uptick in our website traffic. Our public relations activities with
HVM Communications resulted in yesterday’s national network
television segment on NBC’s Today show,” said Justin Hall,
NovaBay’s CEO. “The goal of these cost-efficient programs is to
increase consumer purchases of Avenova through the online channel,
which is where we see the greatest growth opportunity to build on
our No.1 antimicrobial lid and lash spray. These programs
capitalize on consumer outreach with Avenova’s refreshed branding,
vibrant new packaging and lifestyle messaging, as well as recent
independent laboratory results showing Avenova effectively kills
the coronavirus on hard surfaces.”
Yesterday’s Today show segment with lifestyle expert Jenn Falik
included Avenova among “eight better basics that you need to know
about for fall.” Ms. Falik called Avenova a sanitizing spray that
can be used on your entire face, even though it was initially
designed for eyecare. She added that Avenova can be sprayed on your
face throughout the day to kill any germs that result from the
frequent, but often inadvertent, touching of the eyes, nose and
mouth.
NovaBay’s affiliate marketing program with PartnerCentric
connects with affiliates such as consumer-oriented websites or
bloggers to promote Avenova with audience-specific online content.
The affiliates earn commissions of 3% to 8% from resulting Avenova
sales tracked through Avenova.com. Many of the affiliates also
offer coupons or rebates where customers receive a discount or cash
back on their purchases. To participate in Avenova’s affiliate
program, please email affiliates@novabay.com.
“We are excited about the early success of the Avenova program
in generating greater awareness of this innovative antimicrobial
spray,” said Stephanie Harris, PartnerCentric’s Owner and CEO. “We
look forward to building a meaningful partnership with NovaBay and
bringing the combined power of our in-house technology solutions
and tenured management team at PartnerCentric to this
relationship.”
About PartnerCentric
PartnerCentric, Inc. is the largest woman-owned (WBE-certified)
performance marketing agency in the industry. At our core, we build
meaningful relationships beyond borders and aim to be the best
partners for our clients and for each other. Our team, comprised of
proven industry veterans and strategists, connects our clients with
the right partners for long-term success. We utilize a combination
of proprietary in-house technology and innovative, strategic
management to drive the highest ROI for some of the world’s most
respected brands from emerging startups to F500 enterprises. Our
premium management ensures that we are 100% funded by happy
customers and our clients are supported by the most tenured account
managers in the industry, with an average of over 13 years of
experience. Discover our new Control Suite
(www.partnercentric.com/control-suite) and visit
http://www.partnercentric.com to learn more about our team and
services.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, CELLERX® for the aesthetic
dermatology market and NEUTROPHASE® for the wound care market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding all of our
current marketing efforts, any potential financial impact of our
public relations campaigns and affiliate program, as well as
generally the Company’s expected future financial results. These
forward-looking statements are identified by the use of words such
as “uptick,” “goal,” increase,” and “growth” among others. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, the possibility that the available market
for the Company’s products will not be as large as expected, the
Company’s products will not be able to penetrate one or more
targeted markets, revenues will not be sufficient to meet the
Company’s cash needs, and any potential regulatory problems. Other
risks relating to NovaBay’s business, including risks that could
cause results to differ materially from those projected in the
forward-looking statements in this press release, are detailed in
NovaBay’s latest Form 10-Q/K filings with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay informed on
NovaBay’s progress
Like us on Facebook Follow us on Twitter Connect
with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200924005274/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com Investor
Contact LHA Investor Relations Jody Cain 310-691-7100
jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024